



Reporter-based fate mapping in human kidney organoids confirms nephron lineage relationships and reveals synchronous nephron formation

Sara E Howden^{1,2,*} , Jessica M Vanslambrouck^{1,2}, Sean B Wilson¹, Ker Sin Tan¹ & Melissa H Little^{1,2,3,**} 

Abstract

Nephron formation continues throughout kidney morphogenesis in both mice and humans. Lineage tracing studies in mice identified a self-renewing *Six2*-expressing nephron progenitor population able to give rise to the full complement of nephrons throughout kidney morphogenesis. To investigate the origin of nephrons within human pluripotent stem cell-derived kidney organoids, we performed a similar fate-mapping analysis of the *SIX2*-expressing lineage in induced pluripotent stem cell (iPSC)-derived kidney organoids to explore the feasibility of investigating lineage relationships in differentiating iPSCs *in vitro*. Using CRISPR/Cas9 gene-edited lineage reporter lines, we show that *SIX2*-expressing cells give rise to nephron epithelial cell types but not to presumptive ureteric epithelium. The use of an inducible (CreERT2) line revealed a declining capacity for *SIX2*⁺ cells to contribute to nephron formation over time, but retention of nephron-forming capacity if provided an exogenous WNT signal. Hence, while human iPSC-derived kidney tissue appears to maintain lineage relationships previously identified in developing mouse kidney, unlike the developing kidney *in vivo*, kidney organoids lack a nephron progenitor niche capable of both self-renewal and ongoing nephrogenesis.

Keywords CRISPR/Cas9; fate mapping; kidney organoid; lineage tracing; pluripotent stem cell

Subject Categories Development & Differentiation; Stem Cells

DOI 10.15252/embr.201847483 | Received 27 November 2018 | Revised 5

February 2019 | Accepted 8 February 2019

EMBO Reports (2019) e47483

Introduction

Our understanding of kidney morphogenesis is predominantly based on studies performed in model organisms. Gene-knockout and fate-mapping studies, performed largely in mice, have uncovered many

of the fundamental molecular processes underlying kidney development, homeostasis, and disease [1]. While inferences can be made using a well-characterized mammalian model, our capacity to validate the true relevance of lineage relationships or key genetic pathways in human development is hampered by the scarcity of human fetal tissue for experimental purposes. Recent analyses of human fetal kidney have provided important insights and highlighted several differences between humans and mice at both the immunohistochemical and transcriptional levels [2–4]. However, the examination of human fetal tissue is ethically constrained, provides only snapshots at a fixed developmental time-point, and does not represent an ideal platform for evaluating whether differences between human and model organisms convey functional relevance.

The capacity to create a model of the developing human kidney *in vitro* may provide a unique opportunity to better understand nephrogenesis at the molecular level in a human context. This will depend, however, on the accuracy with which these models of human kidney organogenesis recapitulate normal development. Several protocols have now been described for the directed differentiation of human pluripotent stem cells (hPSCs) to kidney organoids [5]. We have established a protocol that generates complex multicellular kidney organoids containing patterning and segmenting nephrons and endothelial, perivascular, and stromal cells [6,7]. After day 25 of differentiation, a single organoid contains up to 100 nephrons, each beginning to show functional maturation with podocyte foot process formation and albumin uptake in proximal tubules. Moreover, kidney organoids exhibit a transcriptional profile that is remarkably similar to first-trimester human fetal kidney [7]. Combined with an ability to generate developing kidney tissue *in vitro*, improvements in the speed and accuracy with which it is possible to edit the genome of hPSCs using CRISPR/Cas9 technology [8] provide a unique opportunity to interrogate the molecular and cellular basis of morphogenesis within kidney organoids to better understand these model systems.

1 Murdoch Children's Research Institute, Parkville, Vic., Australia

2 Department of Paediatrics, The University of Melbourne, Melbourne, Vic., Australia

3 Department of Anatomy and Neuroscience, The University of Melbourne, Melbourne, Vic., Australia

*Corresponding author. Tel: +614 73 019 385; E-mail: sara.howden@mcri.edu.au

**Corresponding author. Tel: +613 993 66 206; E-mail: melissa.little@mcri.edu.au

During kidney morphogenesis in the mouse, new nephrons form throughout development from a mesenchymal population located at the periphery of the developing kidney [9,10]. Marked by expression of *Six2* and *Cited1*, these cells exist in close association with the tips of the branching ureteric epithelium. Nephron formation involves a mesenchymal-to-epithelial transition to form a renal vesicle with this process being accompanied by downregulation of *Six2* [11,12]. In a seminal fate-mapping study performed in mice, Kobayashi *et al* demonstrated that *Six2*-expressing cells represent a multipotent self-renewing nephron progenitor population that, after undergoing mesenchymal-to-epithelial transition, gives rise to all cells of the murine nephron, but not to those within the branching ureteric epithelium [9,10], which is instead derived from a distinct ureteric progenitor population [13].

In this study, we chose to perform a similar fate-mapping analysis of the *SIX2*-expressing lineage in iPSC-derived kidney organoids. Using iPSCs harboring Cre recombinase within the endogenous *SIX2* locus, in addition to a ubiquitously expressed loxP-flanked fluorescence cassette, we demonstrate that *SIX2*-expressing cells can indeed contribute to nephron formation. While *SIX2*-derived cells formed proximal nephron segments, they were absent from the GATA3⁺CDH1⁺ epithelium, consistent with a ureteric epithelium identity for the latter. Importantly, the use of an inducible CreERT2 lineage reporter showed a loss of contribution to new nephrons across time within organoids, highlighting an absence of a nephrogenic zone in such models. Despite this, *SIX2*⁺ cells could contribute to new nephrons late in organoid culture if provided an exogenous WNT signal, suggesting that they retain a nephron progenitor identity across time even in the absence of a ureteric tip. These findings not only improve our understanding of nephrogenesis within kidney organoids, but provide a proof of concept that organoid and gene-editing technologies can be combined to interrogate and dissect human lineage relationships *in vitro*.

Results

SIX2 expression persists throughout kidney organoid differentiation

We first generated a *SIX2* fluorescent reporter iPSC line to evaluate and monitor *SIX2*-expressing cells within differentiating kidney organoids in real time. Here, CRISPR/Cas9 was used to knock-in EGFP at the 3' end of the *SIX2* coding region, linked by the T2A self-cleaving peptide (Fig 1A). Several clonally derived iPSC lines with either heterozygous or homozygous insertion of the EGFP reporter were established using a previously described method that combines reprogramming and gene editing together in a single step [8,14]. Both heterozygous (*SIX2*^{EGFP/+}) and homozygous (*SIX2*^{EGFP/EGFP}) clones, distinguished by PCR analysis (Fig EV1A), were used in subsequent differentiation experiments. Kidney organoids were generated using our previously described protocol [6] (Fig 1B) with two modifications: (i) TeSR-E6 was used instead of APEL as the base differentiation medium, and (ii) a 3D bioprinter was used to generate day 7 aggregates via extrusion bioprinting onto Transwell filters instead of manual transfer with a handheld pipette. This modified protocol enables the generation of large numbers of highly reproducible organoids that are equivalent at the level of morphology,

component cell types, and gene expression to those previously reported via manual generation [preprint: 15]. Reporter gene expression in *SIX2*^{EGFP} organoids was monitored routinely by flow cytometry and fluorescent microscopy and was first detected at approximately days 8–10 of differentiation, consistent with previous reports [13,16,17]. Notably, reporter gene expression was steadily maintained after this time-point, until the cessation of our differentiation experiments at day 25 (Fig 1C and D). Co-localization of EGFP and *SIX2* was confirmed by immunofluorescence (Fig 1E), with EGFP- and *SIX2*-expressing cells restricted largely to the interstitial/mesenchymal compartment (Fig EV1B), as anticipated. Co-localization of EGFP and *SIX2* was also confirmed by RT-PCR analysis of sorted EGFP-expressing and non-expressing fractions (Fig EV1C). Organoids derived from either *SIX2*^{EGFP/+} or *SIX2*^{EGFP/EGFP} iPSCs exhibited highly similar dynamics with respect to reporter gene expression and nephron formation, although reporter gene intensity was greater in *SIX2*^{EGFP/EGFP} kidney organoids (Fig EV1D). EGFP expression was also dependent on CHIR99021 concentration and duration during the first stage of differentiation (Fig EV1E), consistent with previous studies showing that increased WNT signaling during hPSC differentiation induces a more posterior intermediate mesoderm [7]. Organoids generated from cultures treated with < 4 μM CHIR99021 failed to induce *SIX2* expression or any recognizable epithelial structures, whereas differentiations performed with 8 μM CHIR for ≥ 4 days contained the highest fraction of *SIX2*-expressing cells (> 50%). Cultures treated with 6–8 μM CHIR99021 for 4 days formed organoids with the most balanced profile with respect to relative abundance of NEPHRIN⁺ podocytes, LTL⁺ proximal tubules, ECAD⁺ distal tubule structures, and putative GATA3⁺/CDH1⁺ collecting duct epithelium, as determined by whole-mount immunostaining (Fig 1F). This condition was used for all subsequent differentiations.

Single-cell RNAseq of kidney organoids reveals widespread *SIX2*-expression

To examine *SIX2*-expressing cells in greater depth during the process of kidney organoid differentiation, single-cell transcriptome profiling of day 18 and 25 organoids was performed using the 10× Chromium platform. Twenty cell populations emerged from guided clustering analyses using Seurat [18], with several of these pertaining to different nephron segments and cells at various stages of nephrogenesis (Fig 2A, Dataset EV1). Multiple stromal populations were also identified, which expressed collagens *COL1A1* and *COL3A1*, as well as kidney stromal markers *DCN* and *CXCL12*. We note the apparent absence of an endothelial cluster in this dataset, despite clear evidence for this cell type in previous studies [19–21], including in bioprinted organoids [preprint: 15].

With respect to *SIX2*-expressing cells, a distinct population (cluster 9) exhibited strong congruence with human fetal nephron progenitors, as determined by co-expression of several other previously described nephron progenitor markers, including *CITED1*, *DAPL1*, *EYA1*, and *SALL1* [3,13,16] (Fig 2B). Notably, *SIX2* expression was not solely restricted to the putative nephron progenitor cluster, with *SIX2* transcripts detected in scattered cells within several additional clusters, including a subset of the renal stroma, and within an “off-target” population that displayed a muscle-like transcriptional profile (Fig 2C). Interestingly, this *SIX2*-expressing




Figure 1. Analysis of *SIX2*-expressing cells during kidney organoid development.

A Schematic diagram of the targeting strategy for generation of *SIX2* reporter iPSCs. The EGFP gene was inserted just upstream of the *SIX2* stop codon, linked via the self-cleaving T2A sequence.

B Outline of the kidney differentiation protocol used throughout this study.

C Flow cytometry analysis of kidney organoids derived from *SIX2*^{EGFP/EGFP} iPSCs.

D Flow cytometry analysis of *SIX2*^{EGFP/EGFP} kidney organoids shows EGFP/*SIX2* expression emerges after day 7 of differentiation and persists thereafter. Data represent mean \pm SD, $n = 3$.

E Immunostaining of a day 12 *SIX2*^{EGFP/EGFP} kidney organoid confirming co-localization of *SIX2* and EGFP.

F Immunofluorescence of *SIX2*^{EGFP/EGFP} organoid demonstrating expression and correct localization of nephron segment-specific markers for proximal tubules (EPCAM⁺/LTL⁺; blue/green), distal tubules (EPCAM⁺; green), collecting duct (EPCAM⁺/GATA3⁺; green/red), and glomeruli (NPHS1⁺; gray).

Data information: Scale bars = 50 μ m.

muscle-like population was clearly evident in day 25 organoids, but largely absent in earlier day 18 organoids (Fig 2C and D). Compared to day 18, day 25 organoids also showed an overall reduction in both the *SIX2*-expressing nephron progenitor and “early committed nephron” clusters (Fig 2D). Taken together, these findings reveal that *SIX2* is not confined to the presumptive nephron progenitor compartment within human kidney organoids, but also marks several additional distinct cell types, including renal stroma and a muscle-like population which becomes more prevalent as the differentiation proceeds.

Generation of a dual-fluorescence cassette for human fate-mapping studies

To facilitate human fate-mapping experiments in iPSC-derived organoids, we generated a dual-fluorescence gene-targeting cassette

comprising a loxP-flanked EGFP and adjacent mCherry reporter that can be incorporated into the 3' end of the endogenous *GAPDH* coding region (Fig 3A). We have previously shown that this targeting strategy facilitates ubiquitous and consistent transgene expression in hPSCs, both prior to and following differentiation into various different cell types [22]. We first evaluated the functionality of our fluorescence cassette in the human embryonic stem cell line, H9. Following CRISPR/Cas9-mediated knock-in of our targeting cassette, correctly edited cells were identified based on expression of the EGFP reporter (Fig 3A). To validate the Cre-mediated color switching capacity of our dual-fluorescence cassette, EGFP-expressing clones were isolated, expanded, and subsequently transfected with mRNA encoding Cre recombinase. This resulted in the rapid induction of mCherry expression and a corresponding loss of EGFP expression within 8 h post-transfection in > 95% of cells (Fig 3B). Kidney organoids could also be successfully derived from EGFP or




Figure 2. Analysis of *SIX2* expression in kidney organoids by single-cell RNAseq.

- A** tSNE plot representing the merged datasets from single-cell RNAseq analysis of day 18 (1,865 cells) and day 25 (3,500 cells) organoids. Twenty clusters were identified.
- B** A distinct *SIX2*-expressing cluster was identified as a nephron progenitor-like population based on expression of other known markers, including *CITED1*, *DAPL1*, *EYA1*, and *SALL1*.
- C** *SIX2* marks a diverse range of cell types within human kidney organoids with *SIX2* transcripts detected in numerous clusters in both day 18 and day 25 organoids.
- D** Graphical representation showing the cell populations that are enriched or depleted in day 18 versus day 25 kidney organoids.

mCherry-expressing H9 cells, representing cells before and after exposure to Cre recombinase, respectively. We observed maintenance of appropriate reporter gene expression in all component cell types as determined by live fluorescent microscopy and flow cytometry (Fig 3C and D).

Tracing the fate of *SIX2*⁺ cells in human kidney organoids

To examine the fate of *SIX2*-expressing cells in hPSC-derived kidney organoids, we used CRISPR/Cas9-mediated gene editing to insert the Cre recombinase gene into the endogenous *SIX2* locus using the targeting strategy described earlier for generation of *SIX2*^{EGFP} iPSCs. Clonally derived iPSCs with homozygous insertion of Cre recombinase were established using our one-step reprogramming/gene-editing protocol [8] which were subsequently used for knock-in of the dual-fluorescence cassette into the *GAPDH* locus as described above (Fig 4A). Correctly targeted EGFP-expressing colonies, hereafter referred to as *SIX2*^{Cre/Cre}:*GAPDH*^{dual} iPSCs, were identified by fluorescent microscopy, isolated, and expanded for downstream differentiation experiments. Kidney organoids were generated from *SIX2*^{Cre/Cre}:*GAPDH*^{dual} iPSCs and monitored by flow cytometry for reporter gene expression. Cells expressing mCherry could be

detected at approximately day 10 of differentiation, coinciding with activation of endogenous *SIX2* and reporter expression within kidney organoids derived from the *SIX2*^{EGFP} iPSCs described earlier (Figs 4B and 1C). As differentiation progressed, a steady increase in mCherry-expressing cells and a corresponding loss of EGFP-expressing cells were also observed (Fig 4B). Live mCherry⁺/EGFP⁻ cells could also be detected in kidney organoids by fluorescent microscopy, some of which appeared to be localized within epithelial structures (Fig 4C). Whole-mount immunofluorescence of day 25 *SIX2*^{Cre/Cre}:*GAPDH*^{dual} organoids was performed to determine the precise location of mCherry-expressing cells within specific cellular compartments, using markers specific to nephrons (WT1, NPHS1, LTL, CDH1, EPCAM), presumptive ureteric epithelium (GATA3, CDH1), renal interstitium (MEIS1), and endothelium (CD31). *SIX2*-expressing cells were seen to contribute to nephron formation, as evidenced by the appearance of mCherry⁺ cells within LTL⁺ proximal tubules, EPCAM⁺/LTL⁻ distal tubules, and NPHS1⁺ podocytes (Fig 4D). Consistent with our scRNAseq analysis, interstitial cells co-expressing MEIS1 and mCherry were also clearly evident, indicating that *SIX2*⁺ cells give rise to at least a subset of the renal stroma (Fig 4D). Conversely, CD31⁺/mCherry⁺ cells were not observed, indicating that endothelial cells within kidney organoids are not




Figure 3. Generation and characterization of a dual fluorescent reporter construct for downstream lineage tracing experiments.

A Schematic diagram of the targeting strategy. A loxP-flanked EGFP and adjacent mCherry reporter were inserted downstream of the endogenous *GAPDH* coding region, linked via a self-cleaving T2A sequence. In the absence of Cre recombinase, cells constitutively express EGFP.

B The loxP-flanked EGFP gene is deleted following Cre-mediated recombination. Shortly after (< 8 h) the transient transfection of mRNA encoding Cre recombinase, *GAPDH*^{dual} hPSCs permanently switch from EGFP to mCherry reporter gene expression.

C, D Reporter gene expression is maintained in all cell types within kidney organoids generated from *GAPDH*^{dual} hPSCs before and after exposure to Cre, as detected by fluorescent microscopy (C) and flow cytometry (D).

Data information: Scale bar = 50 μ m (panels A and B) and 200 μ m (panel C).

derived from *SIX2*⁺ cells (Fig 4D). Notably, mCherry⁺ cells were excluded from GATA3⁺/CDH1⁺ structures (Fig 4E), which is consistent with a ureteric epithelium-like identity for this population of cells, as previous fate-mapping analyses in mice demonstrate *SIX2*⁺ cells do not give rise to the ureteric epithelium [10]. Using image analysis software, we detected < 1% of mCherry⁺ cells within GATA3⁺/CDH1⁺ epithelium, with most of these events observed at the proximal end of GATA3⁺/CDH1⁺ structures (Fig 4F). Taken together, our findings are consistent with previous studies performed in mice, which show *SIX2*⁺ cells can give rise to all cells of the nephron but not the collecting duct network, which is instead derived from a more anterior ureteric progenitor population [10,13] (Fig 4G).

A *SIX2*-expressing population gives rise to nephrons early in organoid culture but retains nephron-forming capacity across organoid differentiation

In the developing kidney *in vivo*, new nephrons arise throughout fetal development, arising from a self-renewing *Six2*⁺ nephron progenitor population present around the tips of the ureteric epithelium [10]. This process continues until approximately week 36 in humans [23,24] and the first few days after birth in mice

[25], at which point all NPCs have committed to nephron formation. To determine the duration of nephrogenesis across the period of kidney organoid culture, we generated *SIX2* knock-in iPSCs using the tamoxifen-inducible Cre recombinase, CreERT2 [26]. The dual-fluorescence cassette was subsequently inserted into the endogenous *GAPDH* locus of a clonally derived iPSC line harboring a homozygous insertion of CreERT2 (Fig 5A). Day 12 kidney organoids derived from *SIX2*^{CreERT2/CreERT2}:*GAPDH*^{dual} iPSCs were cultured in the presence of 4-hydroxytamoxifen (4-OHT) for 1 h to induce Cre recombination. Activation of the mCherry reporter could be detected by flow cytometry and fluorescent microscopy within 24 h post-treatment (Fig 5B). A dose-dependent trend was also noted, with the number of mCherry⁺ cells positively correlating with 4-OHT concentration as anticipated (Fig 5C). Importantly, no mCherry⁺ cells were observed in the absence of 4-OHT treatment.

To determine if *SIX2*⁺ cells could contribute to nephron formation throughout organoid development, we staggered the labeling of *SIX2*-expressing cells by initiating 4-OHT treatment (1 μ M) at 2-day intervals between days 10 and 18 of differentiation (Fig 6A). Organoids were dissociated at day 25, stained with a directly conjugated EPCAM antibody, and analyzed by flow cytometry to determine the percentage of mCherry⁺ cells localized within epithelial structures.




Figure 4. Fate mapping of the SIX2 population in hPSC-derived kidney organoids.

- A Schematic diagram of the targeting strategy used for generation of SIX2^{Cre/Cre};GAPDH^{dual} iPSCs.
- B Flow cytometry analysis of kidney organoids derived from SIX2^{Cre/Cre};GAPDH^{dual} iPSCs showing induction of mCherry and corresponding loss of EGFP expression.
- C Low (upper panel)- and high-magnification (lower panel) images showing mCherry⁺ cells detected by live fluorescent microscopy in SIX2^{Cre/Cre};GAPDH^{dual} kidney organoids.
- D Immunostaining of SIX2^{Cre/Cre};GAPDH^{dual} kidney organoids shows localization of mCherry cells within proximal (LTL⁺/EPCAM⁺), distal (LTL⁻/EPCAM⁺), and glomerular (NPHS1⁺) nephron segments and within renal stroma (MEIS1⁺) but not within the CD31⁺ vasculature.
- E mCherry⁺ cells were excluded from the presumptive GATA3⁺/ECAD⁺ collecting duct epithelium.
- F Plot showing exclusion of mCherry⁺ cells from GATA3⁺/ECAD⁺ epithelium as determined by image analysis software.
- G Model depicting the separation of nephron and collecting duct lineages during kidney morphogenesis.

Data information: Scale bars = 50 μ m.




Figure 5. Temporal and limited labeling of the *SIX2* lineage using the inducible Cre recombinase, CreERT2.

A Schematic diagram of the targeting strategy used for generation of *SIX2*^{CreERT2/CreERT2};*GAPDH*^{dual} iPSCs.

B mCherry⁺ cells detected by live fluorescent microscopy in *SIX2*^{CreERT2/CreERT2};*GAPDH*^{dual} kidney organoid following 4-OHT induction at day 10 of differentiation. Epithelial mCherry⁺ cells are indicated (white arrow). Scale bar = 50 μm.

C The number of mCherry⁺ cells in kidney *SIX2*^{CreERT2/CreERT2};*GAPDH*^{dual} organoids positively correlates with 4-OHT concentration. Data represent mean ± SD, *n* = 3.

Using this assay, we observed significantly fewer EPCAM⁺ cells within the mCherry⁺ fraction of organoids induced at day 18 compared to those induced at day 10 (Figs 6B and EV2A). While a negative correlation between the time of 4-OHT treatment and EPCAM⁺/mCherry⁺ cells was observed, there was no correlation between time of 4-OHT treatment and the total number of mCherry⁺ cells (Fig EV2B) nor the overall fraction of EPCAM⁺ cells (Fig EV2C). Whole-mount immunofluorescence of day 25 *SIX2*^{CreERT2/CreERT2};*GAPDH*^{dual} organoids was also performed, where we observed mCherry⁺ cells both within EPCAM⁺ structures and the interstitial compartment, but not within the GATA3⁺/EPCAM⁺ epithelium (Fig 6C). In organoids induced early, at day 10, mCherry⁺ cells were easily detected in all nephron epithelial segments and EPCAM⁺/NEPHRIN⁺ podocytes (Fig 6D, early induction). Conversely, in organoids induced at later time-points, mCherry⁺ cells were notably absent within nephron structures and predominantly restricted to the interstitium surrounding them (Fig 6D, late induction). Because our transcriptional profiling data revealed a *SIX2*-expressing cell population with strong similarity to human nephron progenitors in day 18 kidney organoids (see Fig 2), we considered whether an additional CHIR pulse could promote *SIX2*⁺ cells in late (day 18) kidney organoids to undergo nephron commitment. In this set of experiments, kidney organoids induced with 4-OHT at day 18 were subsequently subjected to a 1-h CHIR pulse the following day. When the organoids were harvested 1 week later (day 26) and analyzed by whole-mount immunofluorescence, we could clearly detect mCherry⁺ cells derived from the *SIX2*⁺ lineage in EPCAM⁺ epithelial structures and NEPHRIN⁺ podocytes, whereas mCherry⁺ cells were restricted to the interstitium in control organoids that had not undergone a late CHIR pulse. Collectively,

these findings indicate that the capacity for *SIX2*⁺ cells to contribute to nephron formation is retained across organoid culture, but requires an exogenous differentiation signal such as can be provided via induction of WNT signaling.

Discussion

Organoids derived from hPSCs offer enormous utility in personalized disease modeling and drug testing platforms, while also providing promise for the development of autologous cellular therapies to treat/correct many inherited and acquired diseases. Organoid-based cultures also represent a potential source of human tissue at developmental stages that are typically unavailable for research purposes. In combination with gene-editing technologies, this could facilitate the study of gene function and cellular processes that govern human development *in vitro*. Genome engineering also facilitates studies aimed at characterizing the cell types produced in organoid-based cultures and how well these compare with primary developing tissue, which is imperative for understanding and addressing limitations associated with hPSC-derived tissue.

In this study, we use gene-edited iPSCs to interrogate the *SIX2* lineage in human kidney organoids and to examine how this compares with our existing understanding of mammalian nephrogenesis *in vivo*, which is largely based on studies performed in mice. We first used our previously described kidney organoid differentiation protocol and a *SIX2*^{EGFP} reporter line to monitor *SIX2*⁺ cells in developing kidney organoids. *SIX2*⁺ cells emerged soon after organoid formation and persisted until the termination of differentiation at day 25. Although this contrasts to other previously described




Figure 6. Staggered labeling of *SIX2* lineage shows declining nephrogenic potential of *SIX2*⁺ cells during kidney organoid differentiation.

- A** Outline of the strategy used to interrogate the nephrogenic potential of *SIX2*⁺ cells throughout kidney organoid differentiation.
- B** The percentage of mCherry⁺ cells localized within EPCAM⁺ epithelial structures negatively correlates with the time of 4-OHT initiation, as determined by flow cytometric analysis. Data represent mean \pm SD, $n \geq 3$. Data from day 10 and 18 time-points were obtained from two independent experiments. *P*-value was calculated using unpaired two-sided *t*-test.
- C** Immunostaining of *SIX2*^{CreERT2/CreERT2};GAPDH^{dual} kidney organoids shows mCherry⁺ cells localized within EPCAM⁺ structures (white arrow) and the interstitial compartment (yellow arrow), but not within the GATA3⁺/EPCAM⁺ epithelium.
- D** mCherry⁺ cells derived from the *SIX2*⁺ lineage were detected in all nephron epithelial segments when 4-OHT induction was initiated at day 10 (early induction) but were largely restricted to the interstitium when induced at later time-points (late induction).
- E** In late kidney organoids induced with 4-OHT at day 18, mCherry⁺ cells derived from the *SIX2*⁺ lineage were detected in nephron segments when subjected to a late (day 19) CHIR pulse. mCherry⁺ cells were restricted to the interstitium in control organoids that had not undergone a late CHIR pulse.

Data information: Scale bars = 50 μ m.

differentiation protocols where a rapid loss of *SIX2*⁺ cells is observed soon after the formation of 3D kidney organoids [16], our findings are consistent with a recent study that employed a similar *SIX2*-EGFP reporter iPSC line and kidney organoid protocol, where *SIX2* expression also persisted until the termination of differentiation [27]. Importantly, our findings do not support their hypothesis that the presence of these cells definitively represents a progenitor niche that may supply the organoid with more mature cells over time. Rather, we show that *SIX2* is expressed in a variety of other cell types, and a lack of ongoing nephrogenesis across organoid culture. While single-cell transcriptome profiling of organoids generated in this study did reveal a distinct *SIX2*⁺ population that exhibited strong congruence with human fetal nephron progenitors, *SIX2* expression was also detected in several additional cell clusters. Interestingly, this included an “off-target” muscle-like population that was enriched in late but not early organoids. *SIX2* expression

was also detected in several clusters identified as “renal stroma”. Consistent with this observation, our fate-mapping experiments revealed an obvious *SIX2*⁺ lineage-derived *MEIS1*⁺ stromal population. Although this contrasts sharply with studies performed in mice, where a strict lineage boundary between nephron progenitors and the interstitial progenitor cells that give rise to the renal stroma has been shown to exist [28–30], recent single-cell RNAseq analysis of human fetal kidney has revealed substantial overlap between these two progenitor populations, with co-expression of *SIX2*, *MEIS1*, and *FOXD1* detected within human nephron progenitors [3]. Although difficult to determine definitively whether the co-expression of nephron progenitor and stromal markers is an artifact of our organoid culture system, the findings from this previous study suggest that this may in fact be a true species difference. In mice, the origin of the endothelial population has not been regarded to be the *SIX2*-expressing population and we did not see evidence for

endothelial cells of SIX2 lineage in this study; however, endothelial cell types were low in abundance, and hence, the lineage relationship here remains equivocal and requires more investigation. Further studies are also warranted to determine which sub-populations of the overall SIX2-expressing population can in fact contribute to nephron formation in our organoid model.

The presence of cell clusters with a muscle signature that apparently increase in prevalence with time is difficult to interpret. We would note, however, the prevalent formation of ectopic muscle within Wilms' tumors, a childhood renal neoplasia regarded as showing disrupted development [31]. It has previously been suggested that Wilms' tumor arises as a result of inappropriate differentiation of the nephron progenitors [31,32], with this conclusion recently supported at the single-cell level [33]. It has also been suggested that muscle formation within Wilms' tumors is associated with reductions in WT1 expression. Hence, it is possible that this off-target population is arising from the initial nephron-forming SIX2 population.

Using a lineage tracing iPSC reporter line, we demonstrate that SIX2-expressing cells can contribute to all segments of the developing nephron but are excluded from the distal ends of the GATA3⁺/CDH1⁺ epithelial structures, suggestive of a presumptive ureteric epithelium population in kidney organoids. Of note, not all cells within each nephron had undergone Cre-mediated color switching, with many nephrons comprised of both mCherry⁺ and EGFP⁺ cells. One explanation for this is that Cre recombination may not have been complete. Alternatively, there may be a genuine contribution of both SIX2-expressing and non-expressing cells within forming nephrons. More studies are required to investigate this further.

By using a tamoxifen-inducible variant of Cre recombinase to stagger the labeling of SIX2⁺ cells during organoid differentiation, we noted a significantly reduced capacity for these cells to contribute to nephron formation over time. This suggests human kidney organoids, in contrast to fetal kidney *in vivo*, lack a true nephrogenic zone capable of sustained nephrogenesis. In mice, correct localization of nephron and stromal progenitors around the tips of the ureteric epithelium enables reciprocal inductive signals between these populations. This is required for continued branching of the ureteric epithelium and both nephron progenitor self-renewal and commitment, which drives organogenesis throughout fetal development [12,34]. Interestingly, although SIX2⁺ cells in more mature (day 18) organoids did not contribute to nephron formation, these cells could in fact give rise to nephrons upon the addition of a late (day 19) CHIR pulse. This finding is consistent with the transcriptional profiling of day 18 organoids, where a SIX2-expressing population with strong congruence with human nephron progenitors was identified. However, it suggests that this competent population ceases nephron formation in the absence of an exogenous differentiation signal. Hence, although we demonstrate clear evidence of nephron progenitor commitment in our organoid cultures, a self-renewing niche comprised of a branching ureteric epithelium with corresponding tips and a distinct domain of nephron and stromal progenitors is not evident. This suggests that appropriate spatial organization and/or reciprocal interactions between nephron progenitors, ureteric epithelium, and possibly also the renal stroma are deficient.

Perhaps a more logical strategy for generating kidney organoids with a sustainable nephrogenic niche would be to derive homogeneous populations of nephron and stromal progenitors, and ureteric

epithelium in parallel which could be subsequently combined in 3D culture, in a spatial arrangement that more accurately depicts the developing organ *in vivo*. This strategy was partially recapitulated in a recent study which demonstrated a substantially improved higher-order structure in kidney organoids derived from mouse PSCs, and was highlighted by an impressive capacity for the ureteric epithelium to undergo several rounds of branching morphogenesis [35]. However, while a human branching ureteric epithelium was generated, there was not a successful reciprocal interaction between this epithelium and surrounding presumptive human metanephric mesenchyme, highlighting our limited understanding of the exact conditions required to recapitulate a self-renewing nephron progenitor niche coupled with ongoing productive nephron formation *in vitro*.

In conclusion, our findings show that nephrons within kidney organoids arise from a SIX2-expressing mesenchymal population, as anticipated from previous studies in mice, but also show the absence of ongoing nephrogenesis, likely due to the lack of a peripheral nephrogenic zone. However, at least a subset of SIX2-expressing cells retain nephron-forming capacity longer term and can form nephrons if induced to do so. As such, this represents a proof of concept that gene-editing and organoid technologies can be combined to facilitate fate-mapping studies in differentiating hPSCs, thereby providing a unique opportunity to investigate lineage relationships in real time and in a higher-throughput and more cost-effective manner compared with mammalian models. Additional fate-mapping and CRISPR/Cas9-mediated gene-knockout studies in organoids may facilitate the development of more efficient and robust protocols to generate renal cell types for downstream applications. Indeed, such approaches may also provide deeper insight into human kidney development. While applied to kidney in this instance, such a lineage tracing approach is applicable in other organoid settings in which complex multicellular tissues are formed.

Materials and Methods

Cell lines

Human foreskin fibroblasts (ATCC ID: CRL-2429) were cultured in DMEM (Thermo Fisher Scientific) supplemented with 15% fetal bovine serum (FBS; Hyclone) and 1X MEM Non-Essential Amino Acids Solution (Thermo Fisher Scientific) at 37°C, 5% CO₂, and 5% O₂. All iPSC lines were maintained and expanded at 37°C, 5% CO₂, and 5% O₂ in Essential 8 medium (Thermo Fisher Scientific) on Matrigel-coated plates with daily medium changes and passaged every 3–4 days with EDTA in 1X PBS as previously described [36]. The genomic integrity of iPSCs was confirmed by molecular karyotyping using Infinium CoreExome-24 v1.1 SNP arrays (Illumina), and expression of common pluripotency markers (TRA-1-81, SSEA-4, CD9, OCT4) was confirmed by immunofluorescence and flow cytometry.

Kidney organoid production

The day prior to differentiation, cells were dissociated with TrypLE (Thermo Fisher Scientific), counted using a hemocytometer, and seeded onto Laminin 521-coated 6-well plates at a density of

50×10^3 cells per well in Essential 8 medium. Intermediate mesoderm induction was performed by culturing iPSCs in TeSR-E6 medium (Stem Cell Technologies) containing 4–8 μ M CHIR99021 (R&D Systems) for 4 days. On day 4, cells were switched to TeSR-E6 medium supplemented with 200 ng/ml FGF9 (R&D Systems) and 1 μ g/ml Heparin (Sigma-Aldrich). On day 7, cells were dissociated with TrypLE, diluted fivefold with TeSR-E6 medium, transferred to a 15-ml conical tube, and centrifuged for 5 min at $300 \times g$ to pellet cells. The supernatant was discarded, and cells were resuspended in residual medium and transferred directly into a syringe for bioprinting. Syringes containing the cell paste were loaded onto a NovoGen MMX Bioprinter, primed to ensure cell material was flowing, and user-defined aliquots (5,000–100,000 cells per organoid) were deposited on 0.4- μ m Transwell polyester membranes in 6-well plates (Corning). Following bioprinting, organoids were cultured for 1 h in the presence of 6 μ M CHIR99021 in TeSR-E6 medium in the basolateral compartment and subsequently cultured until day 12 in TeSR-E6 medium supplemented with 200 ng/ml FGF9 and 1 μ g/ml Heparin. From day 12 to day 25, organoids were grown in TeSR-E6 medium without supplementation. Unless otherwise stated, kidney organoids were cultured until harvest at day 25. For induction of CreERT2 protein in kidney organoids derived from SIX2^{CreERT2} iPSCs, 4-hydroxytamoxifen (Sigma-Aldrich) dissolved in ethanol at a concentration of 100 μ M was diluted to working concentration in TeSR-E6. Induction medium (1 ml) was pipetted under the transwell, and individual drops from a 20- μ l pipette were carefully placed on top of the organoids on the filter to ensure complete coverage. Organoids were incubated at 37°C for 1 h. Induction medium was removed by washing three times with TeSR-E6 medium every 10 min and then returned to the media they were in prior to induction.

Vector construction

The SIX2:EGFP vector (pDNR-SIX2:EGFP) carries a targeting cassette encoding the T2A peptide and EGFP gene flanked by ~700 and ~450 bp of sequence corresponding to sequence immediately upstream and downstream of the SIX2 stop codon, respectively. Two gBlocks (Integrated DNA Technologies) encoding the targeting cassette were inserted into the *AatII* and *EcoRI* sites of the pDNR-Dual (Clontech) plasmid vector. The pDNR-SIX2:Cre and pDNR-SIX2:CreERT2 targeting vectors were generated as described above but substituting the Cre recombinase and CreERT2 recombinase genes for EGFP, respectively. The GAPDH targeting vector encoding the dual-fluorescence cassette (pGAPTrap-loxEGFPloxCherry) was generated by inserting sequence encoding the T2A peptide, loxP-flanked EGFP gene with SV40 polyA signal and adjacent mCherry gene with SV40 polyA signal into the *SfiI* and *ClaI* sites of the pGAPTrap-mtagBFP2-IRESMuro plasmid vector (after removal of the mtagBFP2-IRESMuro cassette). A sgRNA plasmid specific to the 3' end of the SIX2 coding region (pSMART-sgRNA-SIX2) was generated by annealing ODNs SIX2_sgRNA1a and SIX2_sgRNA1b followed by ligation into the *BbsI* sites of the pSMART-sgRNA vector [37]. A sgRNA plasmid specific to the 3' end of the GAPDH coding region (pSMART-sgRNA-GAPDH) was generated by annealing ODNs GAPDH_sgRNA1a and GAPDH_sgRNA1b followed by ligation into the *BbsI* sites of the pSMART-sgRNA vector. All plasmids were propagated in DH5-alpha *Escherichia coli* (BIOLINE) and prepared for

transfection using a Plasmid Maxi kit (QIAGEN). See Table 1 for list of ODNs and Table 2 for list of plasmids used in this study.

Generation of knock-in iPSCs

All SIX2 knock-in iPSCs (EGFP, Cre, CreERT2) were derived from human foreskin fibroblasts (ATCC: CRL-2429) using a previously described protocol that combines reprogramming and gene editing in one step [8]. Episomal reprogramming plasmids (pEP4E02SET2K, pEP4E02SEN2L, pEP4E02SEM2K, and pSimple-miR302/367), *in vitro* transcribed mRNA encoding the SpCas9-Gem variant [37], the pSMART-sgRNA-SIX2 plasmid, and either the pDNR-SIX2:EGFP, pDNR-SIX2:Cre, or pDNR-SIX2:CreERT2 targeting vectors were introduced into fibroblast using the Neon Transfection System as described below. *In vitro* transcribed mRNA encoding a truncated version of the EBNA1 protein was also included to enhance nuclear uptake of the reprogramming plasmids [36,38]. Genomic DNA was isolated from resulting iPSCs using the DNeasy Blood & Tissue Kit (QIAGEN) in accordance with the manufacturer's protocol, and PCR analysis was performed using GoTaq Green Master Mix (Promega)

Table 1. Oligonucleotides used in this study.

Name	Sequence
GAPDH_sgRNA1a	CACCGCTTCTCTTGCTCTTGCT
GAPDH_sgRNA1b	AAACAGCAAGAGCACAAGAGGAAGC
SIX2_sgRNA1a	CACCGTCAGCCAACCTCGTGGACC
SIX2_sgRNA1b	AAACGGTCCACGAGGTGGCTGAC
SIX2F	CATCTACCCAGCAACCTGG
EGFPR	GTCCAGCTCGACCAGGATGG
SV40pAF	GCGACTCTAGATCATAATC
SIX2R	GAGTACAAGAGACTGGCAGG
CreR	GAGTTGATAGCTGGCTGGTG

Table 2. Plasmids used in this study.

Name	References	Identifier
pEP4 E02S ET2K	Yu et al [39]	Addgene plasmid #20927
pEP4 E02S EN2L	Yu et al [39]	Addgene plasmid #20922
pEP4 E02S EM2K	Yu et al [39]	Addgene plasmid #20923
pSimple-miR302/367	Howden et al [14]	Addgene plasmid #98748
pSP6-EBNA ^{2A+DBD}	Howden et al [38]	Addgene plasmid #98749
pDNR-SpCas9-Gem	Howden et al [14]	Addgene plasmid #98749
pSMART-sgRNA(Sp)	Howden et al [14]	Addgene plasmid #80427
pGAPTrap-mtagBFP2-IRESMuro	Kao et al [22]	Addgene plasmid #82335
pGAPTrap-loxEGFPloxCherry	This study	TBC
pDNR-Dual	Clontech	N/A (discontinued)
pDNR-SIX2:EGFP	This study	TBC
pDNR-SIX2:Cre	This study	TBC
pDNR-SIX2:CreERT2	This study	TBC

to identify correctly targeted clones. ODNs SIX2F and EGFP flank the 5' recombination junction of SIX2:EGFP knock-in iPSCs, whereas SIX2F and CreR flank the 5' recombination junction of SIX2:Cre and SIX2:CreERT2 knock-ins. ODNs SV40pAF and SIX2R flank the 3' recombination junction of SIX2:EGFP, SIX2:Cre, and SIX2:CreERT2 knock-in iPSCs. Heterozygous and homozygous clones were distinguished using ODNs SIX2F and SIX2R. For knock-in of the dual-fluorescence cassette, the *GAPDH* targeting construct (pGAPTrap-loxEGFPloxCherry) was co-transfected with pSMART-sgRNA-GAPDH and mRNA encoding SpCas9-Gem into hPSCs using the Neon Transfection System as described below. Correctly targeted (EGFP-expressing) clones were identified by fluorescent microscopy.

In vitro transcription

Capped and polyadenylated *in vitro* transcribed mRNA encoding SpCas9-Gem protein [37] was generated using the mMESSAGE mMACHINE T7 ULTRA transcription kit (Thermo Fisher Scientific) according to the manufacturer's recommendations. Plasmid template was linearized with PmeI endonuclease prior to transcription. LiCl was used to precipitate mRNA before resuspension. A truncated version of the EBNA1 protein [38], used to facilitate uptake of reprogramming plasmids, was transcribed using the mMESSAGE mMACHINE SP6 transcription kit (Thermo Fisher Scientific) according to the manufacturer's recommendations.

Cell transfection

Transfections were performed using the Neon Transfection System (Thermo Fisher Scientific). Human fibroblasts or iPSCs were harvested with TrypLE (Thermo Fisher) 2 days after passaging and resuspended in Buffer R at a final concentration of 1×10^7 cells/ml. Electroporation was performed in a 100- μ l tip using 1,400 V, 20 ms, and 2 pulses for human fibroblasts, or 1,100 V, 30 ms, and 1 pulse for human iPSCs. Following electroporation fibroblasts were transferred to 6-well Matrigel-coated plates containing DMEM + 15% FBS and switched to reprogramming medium (TeSR-E7 + 100 μ M sodium butyrate) after 3 days, with medium changes every other day. Electroporated human iPSCs were plated on 6-well Matrigel-coated plates containing Essential 8 medium with 5 μ M Y-27632 (Tocris).

Flow cytometry

Prior to analysis, single kidney organoids were dissociated with 0.2 ml of a 1:1 TrypLE/Accutase solution in 1.5-ml tubes at 37°C for 15–25 min, with occasional mixing (flicking) until large clumps were no longer clearly visible. 1 ml of HBBS supplemented with 2% FBS was added to the cells before passing through a 40- μ M FACS tube cell strainer (Falcon). Flow cytometry was performed using a LSRFortessa Cell Analyzer (BD Biosciences). Data acquisition and analysis were performed using FACSDiva (BD) and FlowLogic software (Invai). Gating was performed on live cells based on forward- and side-scatter analysis.

Whole-mount immunofluorescence

Organoids were transferred to 48-well plates for fixation and immunofluorescence procedures. Fixation was performed using

ice-cold 2% paraformaldehyde (PFA; Sigma-Aldrich) for 20 min followed by 15 min of washing in three changes of phosphate-buffered saline (PBS). For immunofluorescence, blocking and antibody staining incubations were performed on a rocking platform for 3 h at room temperature or overnight at 4°C, respectively. Blocking solution consisted of 10% donkey serum with 0.3% Triton X-100 (TX-100; Sigma-Aldrich) in PBS. See Table 3 for list of antibodies used in this study. Antibodies were diluted in 0.3% TX-100/PBS. Primary antibodies were detected with Alexa Fluor-conjugated fluorescent secondary antibodies (Invitrogen), diluted 1:500. Organoids were washed in at least three changes of PBS for a minimum of 1 h following primary and secondary antibody incubations. Imaging was performed in glass-bottomed dishes (MatTek) with glycerol submersion using either the Zeiss LSM 780 or Dragonfly Spinning Disk confocal microscope.

Single-cell transcriptional profiling and data analysis

Organoids were dissociated as described above (for flow cytometry) and passed through a 40- μ M FACS tube cell strainer. Following centrifugation at 300 g for 3 min, the supernatant was discarded and cells resuspended in 50 μ l TeSR-E6 medium. Viability and cell number were assessed, and samples were run across separate runs on a Chromium Chip Kit (10 \times Genomics). Libraries were prepared using Chromium Single Cell Library kit V2 (10 \times Genomics) and

Table 3. Antibodies used in this study.

Name	Source	Identifier
Mouse monoclonal anti-TRA-1-81	BioLegend	Cat#330706
Mouse monoclonal anti-SSEA-4	BioLegend	Cat#330408
Mouse monoclonal anti-CD9	BD Biosciences	Cat#555371
Rabbit monoclonal anti-OCT4	Abcam	Cat#Ab181557
Rabbit polyclonal anti-RFP (and mCherry)	MBL Medical & Biological Laboratories	Cat#PM005
Biotinylated Lotus Tetragonolobus Lectin	Vector Laboratories	Cat#B-1325
Rabbit polyclonal anti-SIX1	Cell Signaling	Cat#12891
Rabbit polyclonal anti-SIX2	Proteintech Group	Cat#11562-1-AP
Mouse monoclonal anti-MEIS1/2/3	Active Motif	Cat#39795
Mouse anti-EPCAM (Alexa Fluor 488-conjugated)	BioLegend	Cat#324210
Mouse anti-EPCAM (Alexa Fluor 647-conjugated)	BioLegend	Cat#324212
Mouse monoclonal anti-GATA3	Thermo Fisher Scientific	Cat#MA1-028
Goat polyclonal anti-GATA3	R&D Systems	Cat#AF2605
Sheep polyclonal anti-NEPHRIN	R&D Systems	Cat#AF4269
Mouse monoclonal anti-CD31	BD Pharmingen	Cat#550274
Mouse monoclonal anti-E-CADHERIN	BD Biosciences	Cat#610181
Chicken polyclonal anti-GFP	Abcam	Cat#Ab13970

sequenced on an Illumina HiSeq with 100-bp paired-end reads. Cell Ranger (v1.3.1) was used to process and aggregate raw data from each of the samples returning a count matrix. Quality control and analysis was performed in R using the Seurat package (v2.3.1) [18]. Cells with more than 125,000 UMIs, < 500 genes expressed, or more than 20% reads assigned to mitochondrial genes were filtered out. UMI counts, percentage of mitochondrial and ribosomal gene expression, and cell cycle phase identity were regressed out. Genes with less than two counts across the whole dataset were also filtered out. The final dataset had 5,365 cells and 22,105 identified genes. The two samples were merged using a canonical correlation analysis (CCA) using 1,429 genes with the highest dispersion present in both samples. The CCA subspaces were aligned, and the first 25 principal components based on these genes were used to build a graph, which was clustered at a resolution of 1.6. Data from the single-cell transcriptional profiling have been deposited in the Gene Expression Omnibus under accession number GSE119561.

Expanded View for this article is available online.

Acknowledgements

The Murdoch Children's Research Institute is supported by the Victorian Government's Operational Infrastructure Support Program. The MCRI Gene Editing Facility is supported by the Stafford Fox Foundation. MHL is a Senior Principal Research Fellow of the National Health and Medical Research Council, Australia (GNT1136085). This work was supported by the National Institutes of Health, USA (DK107344-01), and the NHMRC (GNT1100970).

Author contributions

SEH and MHL conceived the study and wrote the manuscript; SEH performed gene-editing experiments; SEH, JMV, SBW, and KST performed kidney differentiation experiments; JMV, SBW, and KST performed immunostaining; SBW performed scRNAseq analysis; and all authors assisted in manuscript preparation.

Conflict of interest

M.H.L. is an inventor on a patent associated with kidney organoid generation and has a research contract with and has consulted for Organovo Inc.

References

- Humphreys BD, DiRocco DP (2014) Lineage-tracing methods and the kidney. *Kidney Int* 86: 481–488
- O'Brien LL, Guo Q, Lee Y, Tran T, Benazet JD, Whitney PH, Valouev A, McMahon AP (2016) Differential regulation of mouse and human nephron progenitors by the Six family of transcriptional regulators. *Development* 143: 595–608
- Lindstrom NO, Guo J, Kim AD, Tran T, Guo Q, De Sena Brandine G, Ransick A, Parvez RK, Thornton ME, Basking L et al (2018) Conserved and divergent features of mesenchymal progenitor cell types within the cortical nephrogenic niche of the human and mouse kidney. *J Am Soc Nephrol* 29: 806–824
- Lindstrom NO, McMahon JA, Guo J, Tran T, Guo Q, Rutledge E, Parvez RK, Saribekyan G, Schuler RE, Liao C et al (2018) Conserved and divergent features of human and mouse kidney organogenesis. *J Am Soc Nephrol* 29: 785–805
- Morizane R, Miyoshi T, Bonventre JV (2017) Concise Review: kidney generation with human pluripotent stem cells. *Stem Cells* 35: 2209–2217
- Takasato M, Er PX, Chiu HS, Little MH (2016) Generation of kidney organoids from human pluripotent stem cells. *Nat Protoc* 11: 1681–1692
- Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Chuva de Sousa Lopes SM et al (2015) Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. *Nature* 526: 564–568
- Howden SE, Thomson JA, Little MH (2018) Simultaneous reprogramming and gene editing of human fibroblasts. *Nat Protoc* 13: 875–898
- Boyle S, Misfeldt A, Chandler KJ, Deal KK, Southard-Smith EM, Mortlock DP, Baldwin HS, de Caestecker M (2008) Fate mapping using Cited1-CreERT2 mice demonstrates that the cap mesenchyme contains self-renewing progenitor cells and gives rise exclusively to nephronic epithelia. *Dev Biol* 313: 234–245
- Kobayashi A, Valerius MT, Mugford JW, Carroll TJ, Self M, Oliver G, McMahon AP (2008) Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. *Cell Stem Cell* 3: 169–181
- Short KM, Combes AN, Lefevre J, Ju AL, Georgas KM, Lamberton T, Cairncross O, Rumballe BA, McMahon AP, Hamilton NA et al (2014) Global quantification of tissue dynamics in the developing mouse kidney. *Dev Cell* 29: 188–202
- Little MH, McMahon AP (2012) Mammalian kidney development: principles, progress, and projections. *Cold Spring Harb Perspect Biol* 4: a008300
- Taguchi A, Kaku Y, Ohmori T, Sharmin S, Ogawa M, Sasaki H, Nishinakamura R (2014) Redefining the *in vivo* origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. *Cell Stem Cell* 14: 53–67
- Howden SE, Maufort JP, Duffin BM, Elefanti AG, Stanley EG, Thomson JA (2015) Simultaneous reprogramming and gene correction of patient fibroblasts. *Stem Cell Reports* 5: 1109–1118
- Higgins JW, Chambon A, Bishard K, Hartung A, Arndt D, Brugnano J, Xuan Er P, Lawlor KT, Vanslambrouck JM, Wilson S et al (2018) Bioprinted pluripotent stem cell-derived kidney organoids provide opportunities for high content screening. *bioRxiv* <https://doi.org/10.1101/505396> [PREPRINT]
- Morizane R, Lam AQ, Freedman BS, Kishi S, Valerius MT, Bonventre JV (2015) Nephron organoids derived from human pluripotent stem cells model kidney development and injury. *Nat Biotechnol* 33: 1193–1200
- Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, Parton RG, Wolvetang EJ, Roost MS, Lopes SM et al (2016) Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. *Nature* 536: 238
- Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 36: 411–420
- Phipson B, Er PX, Combes AN, Forbes TA, Howden SE, Zappia L, Yen HJ, Lawlor KT, Hale LJ, Sun J et al (2019) Evaluation of variability in human kidney organoids. *Nat Methods* 16: 79–87
- Combes AN, Zappia L, Er PX, Oshlack A, Little MH (2019) Single-cell analysis reveals congruence between kidney organoids and human fetal kidney. *Genome Med* 11: 3
- Wu H, Uchimura K, Donnelly EL, Kirita Y, Morris SA, Humphreys BD (2018) Comparative analysis and refinement of human PSC-derived

- kidney organoid differentiation with single-cell transcriptomics. *Cell Stem Cell* 23: 869–881 e868
22. Kao T, Labonne T, Niclis JC, Chaurasia R, Lokmic Z, Qian E, Bruveris FF, Howden SE, Motazedian A, Schiesser JV *et al* (2016) GAPTrap: a simple expression system for pluripotent stem cells and their derivatives. *Stem Cell Reports* 7: 518–526
 23. Hinchliffe SA, Sargent PH, Howard CV, Chan YF, van Velzen D (1991) Human intrauterine renal growth expressed in absolute number of glomeruli assessed by the disector method and Cavalieri principle. *Lab Invest* 64: 777–784
 24. Ryan D, Sutherland MR, Flores TJ, Kent AL, Dahlstrom JE, Puelles VG, Bertram JF, McMahon AP, Little MH, Moore L *et al* (2018) Development of the human fetal kidney from mid to late gestation in male and female infants. *EBioMedicine* 27: 275–283
 25. Rumballe BA, Georgas KM, Combes AN, Ju AL, Gilbert T, Little MH (2011) Nephron formation adopts a novel spatial topology at cessation of nephrogenesis. *Dev Biol* 360: 110–122
 26. Indra AK, Warot X, Brocard J, Bornert JM, Xiao JH, Chambon P, Metzger D (1999) Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases. *Nucleic Acids Res* 27: 4324–4327
 27. Borestrom C, Jonebring A, Guo J, Palmgren H, Cederblad L, Forslow A, Svensson A, Soderberg M, Reznichenko A, Nystrom J *et al* (2018) A CRISPR (e)R view on kidney organoids allows generation of an induced pluripotent stem cell-derived kidney model for drug discovery. *Kidney Int* 94: 1099–1110
 28. Kobayashi A, Mugford Joshua W, Krautzberger AM, Naiman N, Liao J, McMahon Andrew P (2014) Identification of a multipotent self-renewing stromal progenitor population during mammalian kidney organogenesis. *Stem Cell Reports* 3: 650–662
 29. Mugford JW, Sipilä P, McMahon JA, McMahon AP (2008) Osr1 expression demarcates a multi-potent population of intermediate mesoderm that undergoes progressive restriction to an Osr1-dependent nephron progenitor compartment within the mammalian kidney. *Dev Biol* 324: 88–98
 30. Levinson R, Mendelsohn C (2003) Stromal progenitors are important for patterning epithelial and mesenchymal cell types in the embryonic kidney. *Semin Cell Dev Biol* 14: 225–231
 31. Miyagawa K, Kent J, Schedl A, van Heyningen V, Hastie ND (1994) Wilms' tumour—a case of disrupted development. *J Cell Sci Suppl* 18: 1–5
 32. Schedl A (2007) Renal abnormalities and their developmental origin. *Nat Rev Genet* 8: 791–802
 33. Young MD, Mitchell TJ, Vieira Braga FA, Tran MGB, Stewart BJ, Ferdinand JR, Collord G, Botting RA, Popescu DM, Loudon KW *et al* (2018) Single-cell transcriptomes from human kidneys reveal the cellular identity of renal tumors. *Science* 361: 594–599
 34. Combes AN, Lefevre JG, Wilson S, Hamilton NA, Little MH (2016) Cap mesenchyme cell swarming during kidney development is influenced by attraction, repulsion, and adhesion to the ureteric tip. *Dev Biol* 418: 297–306
 35. Taguchi A, Nishinakamura R (2017) Higher-order kidney organogenesis from pluripotent stem cells. *Cell Stem Cell* 21: 730–746 e736
 36. Chen G, Gulbranson DR, Hou Z, Bolin JM, Ruotti V, Probasco MD, Smuga-Otto K, Howden SE, Diol NR, Propson NE *et al* (2011) Chemically defined conditions for human iPSC derivation and culture. *Nat Methods* 8: 424–429
 37. Howden SE, McColl B, Glaser A, Vadolas J, Petrou S, Little MH, Elefanti AG, Stanley EG (2016) A Cas9 variant for efficient generation of Indel-free knockin or gene-corrected human pluripotent stem cells. *Stem Cell Reports* 7: 508–517
 38. Howden SE, Warden H, Voullaire L, McLenachan S, Williamson R, Ioannou P, Vadolas J (2006) Chromatin-binding regions of EBNA1 protein facilitate the enhanced transfection of Epstein-Barr virus-based vectors. *Hum Gene Ther* 17: 833–844
 39. Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II, Thomson JA (2009) Human induced pluripotent stem cells free of vector and transgene sequences. *Science* 324: 797–801